BSD Medical is Now Pyrexar Medical

Pyrexar Medical will be an exhibiting sponsor of the PTCOG-NA (Particle Therapy Co-Operative Group - North America) in Miami, Florida, October 14-16, our first participation in this annual event. Pyrexar's interest in proton therapy focused after reading a 2014 article published in the International Journal of Hyperthermia by Prof. Dr. Niloy Datta exploring proton therapy and hyperthermia.

Since then, Pyrexar placed a BSD-2000 Deep Regional Hyperthermia System at the University of Maryland Proton Center.  The first installation in the world to offer both a proton therapy system and hyperthermia system under the same roof.  This installation, along with further clinical study, will move us closer to understanding the relationship of protons combined with focused heating.

For more information on attending the upcoming PTCOG-NA conference, follow the link.

In the last few weeks, Pyrexar products were presented at conferences in Warsaw, Poland; Miami, Florida; Barcelona, Spain; and Münster, Germany.  So thankful for our global partners' efforts to educate oncologists and physicists on the benefits of hyperthermia in the treatment of cancer. We wanted to share a few images of these events with you.

ESHO - Warsaw, Poland

Pyrexar ESHO Award

The ESHO-Pyrexar Award, presented by Dr. Sennewald Medizintechnik Gmbh, is awarded annually for outstanding contributions to hyperthermic oncology, education, and scientific achievement. This year's recipient is Prof. Dr. med. Lars Lindner.  Dr. Lindner is a respected thermal oncologist and researcher, well known for the landmark study "Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma" published in Jama earlier this year.  We congratulate him and his team for their contributions to thermal medicine. More information about ESHO (European Society for Hyperthermic Oncology) can be found here.

SEOR - Barcelona, Spain

Pyrexar's first time at the SEOR (Spanish Society of Radiation Oncology) in Spain, represented by our distributor Magna Medic Systems based in Málaga, Spain.  The organization has been making tremendous strides in the introduction of hyperthermia to oncologists in the region.

DEGRO - Münster, Germany

Our distribution partner, Dr. Sennewald Medizintechnik Gmb, was a silver sponsor at DEGRO (German Society of Radiation Oncology) and held a lunch symposium focused on reimbursement issues in Germany.

ABS - Miami Florida

Pyrexar's first engagement at the ABS (American Brachytherapy Society).  Our goal is to demonstrate that adding hyperthermia as an adjunct to brachytherapy boosted the effectiveness of this radiotherapy treatment without interrupting workflow. It was an excellent show, and we will be back next year.

Magna Medic Systems / Pyrexar Medical at SEOR XX

Pyrexar represented by our distribution partner Magna Medic Systems at the XX Congreso SEOR in Santiago de Compostela, Spain.

The Sociedad Española de Oncología Clínica (Spanish Society of Radiation Oncology) is an association of more than 1000 specialists from Spain (including doctors in training) whose work is developed primarily in the treatment of cancer through the use of ionizing radiation. The annual meeting is an excellent opportunity to share ideas and data from around the world.

Earlier this year, Magna Medic placed a BSD-500 Superficial Hyperthermia unit at the Clinica Sagrada Familia in Barcelona, Spain. The facility boasts a 135 bed, 225,000 sqft facility with eight specialty surgical suites to support cardiac surgery, neurosurgery, ophthalmology, general surgery, and traumatology. Clinica Sagrada currently performs over 12,000 surgeries per year.

We are very thankful for the hard work the Magna Medic team has done to bring hyperthermia to Spain.

Pyrexar will be exhibiting at this year's ABS (American Brachytherapy Society) annual meeting in Miami, Florida. The conference held at the Intercontinental Miami hotel, June 13th through the 15th.

This is our first time exhibiting at the conference, and we believe we have a compelling solution to offer. HDR (high dose rate) brachytherapy and hyperthermia share some of the same market challenges. The bottom line is that brachytherapy plus hyperthermia improve cancer patient outcomes.

Like hyperthermia, brachytherapy is a sub-specialty that requires a specific skill set to treat patients. And like hyperthermia, brachytherapy is known to produce increased tumor control without an increase in toxicity. Product planning for hyperthermia is very similar, and the system utilizes the existing brachy catheters placed during HDR.